IVF Leave in the UK and Europe: Where the Right Exists in 2026

A Continent of Different Answers to the Same Question

A worker undergoing IVF in Europe is operating under a fundamentally different legal architecture than a worker undergoing IVF in the United States. Most European countries have stronger baseline labor protections, longer statutory sick leave entitlements, and -- in several cases -- specific statutory provisions for medically assisted reproduction. The result is that the question "do I have a right to time off for IVF" produces a different answer in nearly every European jurisdiction.

A few have specific statutes that name assisted reproduction. France is the clearest example. A few have anti-discrimination frameworks that do most of the protective work without naming IVF directly. The UK falls into this category. A few have generous generic sick leave that absorbs the question without ever needing to address it specifically. Germany sits here. And a few have done landmark work in adjacent areas -- menstrual health, pregnancy loss, surrogacy -- that signals the direction of travel even when IVF itself is not yet the named subject.

This article walks through the major European jurisdictions, what the statutory or common-law right looks like in each, where the gaps are, and what practical workplace strategies tend to work in 2026.

This article provides general information about leave rights. It is not legal advice. For your specific situation, consult an employment attorney or your state labor department.

United Kingdom: No Specific Statute, Strong Case Framework

The UK does not have a specific statutory right to time off for IVF treatment. ACAS confirms this directly: "There's no legal right for time off work for IVF treatment or related sickness." There is no equivalent of France's Article L1225-16. The Employment Rights Act 1996 does not name fertility treatment. The Equality Act 2010 does not list infertility as a protected characteristic.

What the UK has instead is a layered framework that does most of the work in practice:

Generic sick leave. UK workers have a statutory right to Statutory Sick Pay (SSP) when they meet the qualifying conditions, and most employers offer contractual sick pay that is more generous. IVF-related illness -- whether from medication side effects, the procedure itself, or post-procedure recovery -- is treated as ordinary sickness absence and qualifies workers for whatever sick pay their employer provides.

Equality Act protections after embryo transfer. This is the legal core. Once an embryo has been transferred and the worker is in the so-called two-week wait, ACAS guidance treats the worker as pregnant: "When a worker reaches the 'embryo transfer' stage, they have the same rights as a pregnant worker. From this stage they'll have the same rights as any pregnant person, including leave, pay, and protection from pregnancy and maternity discrimination." The leading European authority is Mayr v Bäckerei und Konditorei Gerhard Flöckner OHG (Case C-506/06), a 26 February 2008 Grand Chamber decision of the European Court of Justice. The Court held that, although a worker between follicular puncture and embryo transfer is not yet legally pregnant under the Pregnant Workers Directive 92/85/EEC, dismissal on the basis of IVF treatment at that advanced stage is direct sex discrimination under the Equal Treatment Directive 76/207/EEC (now recast as Directive 2006/54/EC) -- because only women undergo IVF. UK courts and tribunals follow this sex-discrimination approach; the post-transfer "treated as pregnant" status that triggers full Equality Act pregnancy/maternity protection comes from ACAS guidance and UK case law, not from Mayr itself.

ACAS guidance. The UK's Advisory, Conciliation and Arbitration Service has published explicit guidance on IVF and fertility treatment. The guidance is non-binding but influential, and notes that "there's no legal right to paid time off for IVF appointments. Employees might not get paid for it or have to make up the time later, depending on their contract." ACAS recommends that employers treat IVF appointments and any related sickness in the same way they would treat any other medical appointment or sickness, and encourages employees to talk with their employer about the time off they need.

The practical UK pattern is therefore: sick leave for IVF-related illness, antenatal-equivalent treatment after embryo transfer, ACAS-influenced employer policies for everything in between, and a discrimination claim available where things go badly.

Important: UK employers that follow ACAS guidance generally treat the early stages of IVF (monitoring appointments, injections, retrieval) as a category requiring at least some accommodation, even where the formal statutory hook is sick leave rather than a specific IVF leave. Employers that ignore ACAS guidance are taking on greater discrimination-claim risk if the cycle later runs into a dispute.

France: The Cleanest Statutory Right

France has the cleanest statutory right in Europe for medically assisted reproduction. Article L1225-16 of the Code du Travail provides that an employee undergoing assistance médicale à la procréation (AMP) -- the French legal term for medically assisted reproduction, which includes IVF, IUI, and related techniques -- is entitled to authorized absence for the medical procedures required by the protocol.

The provision has several specific features:

Authorized absence with no loss of pay. The leave is paid. Time off for AMP-related medical examinations is treated as actual working time for purposes of pay, paid-leave accrual, and seniority calculations.

Coverage of the partner. The statute extends the right to the spouse of the person undergoing AMP, or to a partner linked by a civil solidarity pact (PACS) or living maritally with her. The partner is entitled to authorized absence for up to three of the required medical examinations or procedures per AMP protocol. This is one of the few European statutes that explicitly addresses partner attendance.

Anti-discrimination protection. Article L1225-3-1 prohibits discrimination on the basis of an employee's recourse to AMP, and was further strengthened in July 2025 to cover any employee (woman or man) engaged in a parental project through AMP or adoption. This is a discrete statutory protection separate from the general anti-discrimination framework.

No specific cap on the number of cycles. The statute does not limit the right to a specific number of treatment cycles, though the leave only applies to medically necessary AMP procedures.

The combination of the leave right and the discrimination protection makes France one of the strongest jurisdictions in Europe for IVF patients in employment. The statute does not solve every problem -- partners are limited to three procedures per protocol, the leave only covers medically necessary appointments, and employer practice varies in interpretation -- but the legal floor is materially higher than in the UK or most other European jurisdictions.

Spain: The Menstrual Leave Precedent and What It Implies

Spain made international headlines in 2023 with Ley Orgánica 1/2023, which became the first law in Europe to provide statutory paid leave for severe menstrual pain. The headline was menstrual leave, but the structural significance for fertility law is broader.

The law amended Spain's social security framework to recognize secondary incapacitating menstruation -- including dysmenorrhea associated with conditions like endometriosis, fibroids, adenomyosis, polycystic ovaries, or pelvic inflammatory disease -- as a special situation of temporary incapacity (incapacidad temporal). The benefit is paid by Social Security from the first day of work leave, rather than only after the conventional waiting period that applies to other illnesses. This is narrower than a fertility leave statute but substantively important for two reasons.

First, it broke the precedent against legislating reproductive-health-specific leave. Before 2023, the European pattern had been to treat reproductive health under generic sick leave frameworks. Spain's law established that a member state can carve out specific reproductive-health categories for differentiated treatment.

Second, the conditions covered by Ley Orgánica 1/2023 -- endometriosis, severe dysmenorrhea -- are conditions that frequently coincide with infertility. A worker pursuing IVF for endometriosis-related infertility may qualify for the menstrual leave provisions during pre-treatment phases of the cycle, in addition to whatever generic sick leave applies during the IVF cycle itself.

For IVF specifically, Spanish workers rely primarily on generic sick leave (incapacidad temporal) under the social security system, supplemented by the menstrual-leave provisions where applicable, and by anti-discrimination protections under Spain's gender equality framework. There is no France-style specific statute for AMP, but the overall framework is comparatively strong.

Germany: Generic Sick Leave Doing Most of the Work

Germany has no specific statutory right to time off for fertility treatment. What it has instead is one of the most generous generic sick-leave frameworks in Europe, which absorbs the question without ever needing to address it directly.

Under the Entgeltfortzahlungsgesetz (Continued Remuneration Act), employees who are unable to work due to illness are entitled to up to six weeks of full pay (Entgeltfortzahlung) from the employer, after which the statutory health insurance system (Krankenkasse) provides extended sickness benefits (Krankengeld) under § 48 SGB V at approximately 70% of regular pay for up to 78 weeks within a three-year period for the same illness.

For IVF specifically, this means:

Medical appointments. The Mutterschutzgesetz (Maternity Protection Act) only protects from confirmed pregnancy onward, so the pre-transfer monitoring side of IVF is generally handled through employer flexibility or, where required, a sick note (Arbeitsunfähigkeitsbescheinigung) from the treating physician.

Egg retrieval and transfer. These procedures and any associated incapacity are covered as ordinary sickness absence with full pay during the six-week employer-paid window.

Complications. Hyperstimulation reactions and other IVF complications are handled the same way -- as ordinary sickness with the same six-week full-pay protection.

Anti-discrimination. The Allgemeines Gleichbehandlungsgesetz (AGG, General Equal Treatment Act) provides anti-discrimination protections, and German labour case law has treated IVF-related dismissal as sex discrimination in line with the European framework set by Mayr.

The German pattern is therefore strong on financial protection (six weeks at full pay) but lacks the specific statutory acknowledgment that France provides. In practice, most German workers report that the generic system works adequately for IVF, with the main pain point being employer-side discretion on routine monitoring appointments rather than the procedures themselves.

Italy, Netherlands, Sweden: Variations on the Theme

The pattern continues across the rest of Western Europe with notable variations.

Italy. No specific IVF leave statute. Generic sick leave (malattia) applies and is reasonably generous. The Italian framework was strengthened by the 2004 fertility law (Legge 40/2004), but that law primarily addresses the medical and ethical regulation of assisted reproduction rather than employment leave. Workplace protection rests largely on generic sick leave plus anti-discrimination.

Netherlands. No specific IVF leave statute. Under Article 7:629 of the Burgerlijk Wetboek, employees on sick leave are entitled to at least 70% of their wages from the employer for up to 104 weeks (collective agreements often top this up to full pay for the first year). This generosity tends to absorb IVF-related needs without specific statutory provision. The Algemene wet gelijke behandeling (Equal Treatment Act) provides the anti-discrimination overlay.

Sweden. No specific IVF leave statute. Sweden's sick leave system (sjukpenning) provides paid leave for genuine medical incapacity, and Sweden's overall family policy framework is among the most progressive in the world. IVF treatment is widely covered by the public health system, and the employment treatment of IVF-related absences is handled within the generic sick leave framework. Sweden's Diskrimineringslagen (Discrimination Act) provides further protection.

Denmark. Similar pattern to Sweden. No specific IVF statute, generous sick leave, strong anti-discrimination framework, and public funding for fertility treatment that removes much of the financial pressure.

Belgium. No specific IVF statute. Belgian workers rely on generic sick leave with employer-paid period and subsequent state benefits. Public funding of IVF (one of the most generous in Europe) is the bigger story than employment leave specifically.

The pattern across these jurisdictions is consistent. None of them treats IVF as a separate statutory category for leave purposes. All of them have generic sick-leave frameworks that are generous enough to handle IVF-related absences. The variation is mostly in the strength of the public funding that sits alongside the leave -- which is the implicit reason these jurisdictions have not felt pressure to legislate IVF-specific leave the way the UK and US debates have.

Comparative Snapshot

The contrast with the United States is the clearest takeaway. American IVF patients operate without a federal sick leave floor at all and depend on a state-by-state patchwork that we have walked through in our piece on fertility leave laws by US state. European IVF patients almost universally have generous statutory sick leave as the baseline, even when no IVF-specific statute exists. The conversation in Europe is about whether to add fertility-specific provisions on top of an already generous floor; the conversation in the United States is about whether to build a floor at all.

Where Anti-Discrimination Does the Heavy Lifting

In every European jurisdiction without a specific IVF statute, the anti-discrimination framework does much of the protective work that statutory leave does in France. The structural argument runs through three steps.

Step one: IVF is reproductive medicine. Treatment for infertility is, by medical and statutory definition, treatment of a condition predominantly affecting one sex, and therefore differential treatment of IVF patients is potentially sex discrimination.

Step two: Mayr establishes sex-discrimination protection from retrieval onward. The 26 February 2008 Grand Chamber decision in Mayr (C-506/06) held that dismissing a worker because of IVF treatment at the advanced stage between follicular puncture and embryo transfer is direct sex discrimination under the Equal Treatment Directive 76/207/EEC -- because only women undergo IVF. The Court expressly declined to extend pregnant-worker status under the Pregnant Workers Directive 92/85/EEC to that pre-transfer period; legal pregnancy status begins at transfer. UK, Irish, and most EU jurisdictions follow this approach.

Step three: Discrimination on the basis of recourse to fertility treatment is therefore actionable. A worker who is dismissed, denied promotion, or otherwise treated less favorably because of IVF treatment can typically bring a sex discrimination claim under the relevant national anti-discrimination law, even without a specific IVF leave statute.

This three-step argument is what makes the UK framework function despite the absence of a specific statute. It is also what makes the German, Italian, Spanish, and Dutch frameworks function. The protection is not as crisp as a specific statutory right, but it is genuine and has produced significant case law.

Practical Workplace Advice for European Workers

A few patterns that hold across jurisdictions:

Get a medical certificate early. Whether the legal mechanism is generic sick leave, AMP authorization in France, or anti-discrimination protection elsewhere, a clear written certificate from the treating clinician is the document that makes everything else work.

Frame the request in writing. Even where the law does not require a written request, a written record of the request and the employer's response is essential if the situation later becomes contested. This is the same documentation discipline that applies to contested leave requests generally.

Distinguish appointments from procedures in the request. The legal protection for short monitoring visits is different from the protection for retrieval and transfer. Most European frameworks accommodate both, but the categorization matters for documentation purposes.

Know which framework you are invoking. In France, invoking Article L1225-16 explicitly is more effective than treating the request as generic sick leave. In the UK, invoking the post-transfer Equality Act framework after embryo transfer is more effective than treating that period as generic sickness. The legal lever changes with the phase of treatment.

Plan around the cycle, not just the procedure. A typical IVF cycle involves 4 to 8 weeks of activity, not a single day off for retrieval. Strong European sick leave systems accommodate this, but the planning still helps -- particularly when coordinating with annual leave planning for the rest of the year.

A Note on Surrogacy and Adoption

European frameworks for surrogacy and adoption leave are increasingly complex and vary substantially across jurisdictions. The UK's Surrogacy Arrangements Act and the Children and Families Act 2014 provide adoption-equivalent leave for intended parents in surrogacy arrangements. France's framework treats surrogacy more restrictively. Other jurisdictions have intermediate positions. We have covered this terrain in detail in surrogacy leave rights for intended parents.

For workers considering cross-border treatment -- which is common in Europe given variation in public funding and legal availability -- the leave framework that applies is generally the framework of the country where the worker is employed, not the country where treatment is received. This matters for advance planning, particularly for surrogacy arrangements where the intended parents' employment law may differ from the surrogate's.

Closing

The European IVF leave landscape in 2026 is characterized by strong generic sick leave frameworks across most jurisdictions, a small number of specific statutory rights (France being the clearest), and a robust anti-discrimination overlay derived from EU law and national equality acts. The United States remains the outlier among developed economies in lacking both a federal sick leave floor and a federal fertility-specific statute, with the result that American workers depend on a state-by-state patchwork that no European worker has to navigate.

For European workers planning a cycle, the practical advice is to identify which national framework applies, secure clinician documentation early, frame the request in the legal terms that the relevant national framework recognizes, and coordinate with annual leave planning for the rest of the year. For workers comparing systems across borders -- a not-uncommon situation given the prevalence of cross-border fertility treatment in Europe -- the framework that protects employment is the framework of the country where the worker is employed.

Try the free optimizer at leavewise.co

If a fertility year is approaching and you are working out how the European sick leave framework in your country will sit alongside your annual leave, the optimizer can help. Public holidays, bridge days, and well-placed annual leave still matter even where statutory sick leave is generous -- they are what determines whether the rest of the year feels manageable around the cycle. Planning the whole picture up front, not just the procedure days, is what makes the difference.

Disclaimer

This article summarizes employment-law and fertility-regulation frameworks across multiple jurisdictions as of May 2026. Laws and regulations change frequently, and the rules vary dramatically by country and individual employer policy. National legislatures pass new statutes; courts reinterpret old ones; collective agreements and union contracts may grant additional rights or impose different procedures than those described here.

Use this article as a starting point, not a legal opinion. Before making decisions that depend on your leave entitlements:

• For UK rules, check gov.uk and ACAS
• For EU/EEA rules, check your national labor ministry and EUR-Lex
• For French AMP rules specifically, check Légifrance and the Code du travail
• Read your employer's specific leave policies (and any collective bargaining agreement)
• Consult a qualified employment attorney for situations involving termination, retaliation, or denied accommodations

Nothing in this article constitutes legal advice or creates an attorney-client relationship.